Clearside Biomedical licenses microinjector to Aura Biosciences

Clearside Biomedical (NSDQ:CLSD) said today that it licensed its microinjector technology to Aura Biosciences for use with Aura drug candidates in treating ocular cancers. Alpharetta, Ga.-based Clearside’s Suprachoroidal Space Microinjector is designed to deliver therapeutics into the suprachoroidal space between the sclera and choroid of the eye. Aura, based in Cambridge, Mass., is developing viral nanoparticle conjugates designed to seek out and eliminate cancer cells. Get the full story at our sister site, Drug Delivery Business News
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Optical/Ophthalmic Research & Development Aura Biosciences Clearside Biomedical Source Type: news